Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors

K Schultz; K Nilsson; Jørgen Erik Nielsen; S G Lindquist; Lena Elisabeth Hjermind; B B Andersen; A Wallin; C Nilsson; A Petersén

doi:10.1111/j.1468-1331.2009.02841.x

Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors

K Schultz, K Nilsson, Jørgen Erik Nielsen, S G Lindquist, Lena Elisabeth Hjermind, B B Andersen, A Wallin, C Nilsson, A Petersén

Medical Genetics Program

19 Citations (Scopus)

Abstract

Background: Previous studies have indicated that transthyretin (TTR) levels in cerebrospinal fluid (CSF) are altered in depression and dementia. The present study aimed to investigate whether CSF TTR can be used to discriminate between patients with Alzheimer's disease (AD) and patients with dementia with Lewy bodies (DLB) with or without medication, as well as to reveal whether CSF TTR correlates with depression in dementia. Methods: CSF samples from 59 patients with AD, 13 patients with DLB and 13 healthy controls were collected, and biochemical analysis was performed. Subjects were assessed for the presence of depression. Results: No significant differences in CSF TTR were found between AD, DLB, and control subjects or between depressed and non-depressed dementia patients. Interestingly, we found a significant reduction in CSF TTR (14%) in AD patients who were medicated with cholinesterase inhibitors compared to those AD patients who were not. Conclusions: Significant reductions in CSF TTR were found after cholinesterase inhibitor treatment in patients with AD compared to untreated individuals. CSF TTR was unaltered in patients with DLB and had no relationship to depression in the present cohort with dementias.

Original language	English
Journal	European Journal of Neurology
Volume	17
Issue number	3
Pages (from-to)	456-60
Number of pages	4
ISSN	1351-5101
DOIs	https://doi.org/10.1111/j.1468-1331.2009.02841.x
Publication status	Published - Mar 2010

Access to Document

10.1111/j.1468-1331.2009.02841.x

Cite this

Schultz, K., Nilsson, K., Nielsen, J. E., Lindquist, S. G., Hjermind, L. E., Andersen, B. B., Wallin, A., Nilsson, C., & Petersén, A. (2010). Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. European Journal of Neurology, 17(3), 456-60. https://doi.org/10.1111/j.1468-1331.2009.02841.x

Schultz, K, Nilsson, K, Nielsen, JE , Lindquist, SG, Hjermind, LE, Andersen, BB, Wallin, A, Nilsson, C & Petersén, A 2010, 'Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors', European Journal of Neurology, vol. 17, no. 3, pp. 456-60. https://doi.org/10.1111/j.1468-1331.2009.02841.x

@article{81b24130956611df928f000ea68e967b,

title = "Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors",

abstract = "Background: Previous studies have indicated that transthyretin (TTR) levels in cerebrospinal fluid (CSF) are altered in depression and dementia. The present study aimed to investigate whether CSF TTR can be used to discriminate between patients with Alzheimer's disease (AD) and patients with dementia with Lewy bodies (DLB) with or without medication, as well as to reveal whether CSF TTR correlates with depression in dementia. Methods: CSF samples from 59 patients with AD, 13 patients with DLB and 13 healthy controls were collected, and biochemical analysis was performed. Subjects were assessed for the presence of depression. Results: No significant differences in CSF TTR were found between AD, DLB, and control subjects or between depressed and non-depressed dementia patients. Interestingly, we found a significant reduction in CSF TTR (14%) in AD patients who were medicated with cholinesterase inhibitors compared to those AD patients who were not. Conclusions: Significant reductions in CSF TTR were found after cholinesterase inhibitor treatment in patients with AD compared to untreated individuals. CSF TTR was unaltered in patients with DLB and had no relationship to depression in the present cohort with dementias.",

author = "K Schultz and K Nilsson and Nielsen, {J{\o}rgen Erik} and Lindquist, {S G} and Hjermind, {Lena Elisabeth} and Andersen, {B B} and A Wallin and C Nilsson and A Peters{\'e}n",

year = "2010",

month = mar,

doi = "10.1111/j.1468-1331.2009.02841.x",

language = "English",

volume = "17",

pages = "456--60",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors

AU - Schultz, K

AU - Nilsson, K

AU - Nielsen, Jørgen Erik

AU - Lindquist, S G

AU - Hjermind, Lena Elisabeth

AU - Andersen, B B

AU - Wallin, A

AU - Nilsson, C

AU - Petersén, A

PY - 2010/3

Y1 - 2010/3

N2 - Background: Previous studies have indicated that transthyretin (TTR) levels in cerebrospinal fluid (CSF) are altered in depression and dementia. The present study aimed to investigate whether CSF TTR can be used to discriminate between patients with Alzheimer's disease (AD) and patients with dementia with Lewy bodies (DLB) with or without medication, as well as to reveal whether CSF TTR correlates with depression in dementia. Methods: CSF samples from 59 patients with AD, 13 patients with DLB and 13 healthy controls were collected, and biochemical analysis was performed. Subjects were assessed for the presence of depression. Results: No significant differences in CSF TTR were found between AD, DLB, and control subjects or between depressed and non-depressed dementia patients. Interestingly, we found a significant reduction in CSF TTR (14%) in AD patients who were medicated with cholinesterase inhibitors compared to those AD patients who were not. Conclusions: Significant reductions in CSF TTR were found after cholinesterase inhibitor treatment in patients with AD compared to untreated individuals. CSF TTR was unaltered in patients with DLB and had no relationship to depression in the present cohort with dementias.

AB - Background: Previous studies have indicated that transthyretin (TTR) levels in cerebrospinal fluid (CSF) are altered in depression and dementia. The present study aimed to investigate whether CSF TTR can be used to discriminate between patients with Alzheimer's disease (AD) and patients with dementia with Lewy bodies (DLB) with or without medication, as well as to reveal whether CSF TTR correlates with depression in dementia. Methods: CSF samples from 59 patients with AD, 13 patients with DLB and 13 healthy controls were collected, and biochemical analysis was performed. Subjects were assessed for the presence of depression. Results: No significant differences in CSF TTR were found between AD, DLB, and control subjects or between depressed and non-depressed dementia patients. Interestingly, we found a significant reduction in CSF TTR (14%) in AD patients who were medicated with cholinesterase inhibitors compared to those AD patients who were not. Conclusions: Significant reductions in CSF TTR were found after cholinesterase inhibitor treatment in patients with AD compared to untreated individuals. CSF TTR was unaltered in patients with DLB and had no relationship to depression in the present cohort with dementias.

U2 - 10.1111/j.1468-1331.2009.02841.x

DO - 10.1111/j.1468-1331.2009.02841.x

M3 - Journal article

C2 - 19922456

SN - 1351-5101

VL - 17

SP - 456

EP - 460

JO - European Journal of Neurology

JF - European Journal of Neurology

IS - 3

ER -

Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors

Abstract

Access to Document

Fingerprint

Cite this